Impact of G-CSF on FOLFIRINOX-induced neutropenia prevention: a population PK/PD approach.
Fiche publication
Date publication
mai 2020
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr VINCENT Julie, Dr BENGRINE-LEFEVRE Leila, Pr SCHMITT Antonin
Tous les auteurs :
Macaire P, Paris J, Vincent J, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A
Lien Pubmed
Résumé
Granulocyte colony-stimulating factor (G-CSF) is frequently prescribed to prevent chemotherapy-induced neutropenia, but the administration schedule remains empirical in case of bi-monthly chemotherapy such as FOLFIRINOX regimen. This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine effect of different G-CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G-CSF dosing schedule.
Mots clés
Adverse Drug Reactions, Modelling and Simulation, Oncology, Population analysis
Référence
Br J Clin Pharmacol. 2020 May 9;: